Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021 - Wu, Qing; Qian, Wei; Sun, Xiaoli; Jiang, Shaojie (Journal of hematology and oncology, 2022)
Keywords: Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Binding sites; Biological Products - therapeutic use; Biopharmaceuticals; Breast cancer; Cancer; Cancer therapies; Clinical trials; Development and progression; Drug approval; Drug development; Drug resistance; Drug therapy; Epidermal growth factor; FDA approval; Gene therapy; Health aspects; Hematology; Humans; Immune checkpoint; Immune checkpoint blockades; Immune Checkpoint Inhibitors; Immunoconjugates - therapeutic use; Immunosuppressive agents; Immunotherapy; Kinases; Lung cancer; Metastasis; Monoclonal antibodies; Mutation; Neoplasms - drug therapy; Oncology; Pharmaceutical Preparations; Proteins; Receptor tyrosine kinase inhibitors; Respiratory agents; Review; Solid tumors; The United States Food and Drug Administration; Tumors; Tyrosine; United States; United States Food and Drug Administration; Vaccines; United States; Immune checkpoint blockades; Receptor tyrosine kinase inhibitors; Solid tumors; The United States Food and Drug Administration